A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerPanagiotis A. Konstantinopoulos, Ronnie Shapira‐Frommer, Samuel McNeely et al.|Gynecologic Oncology|2022Cited by 66